84 related articles for article (PubMed ID: 17249580)
21. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
Stein L; Roy K; Lei L; Kaushal S
Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
[TBL] [Abstract][Full Text] [Related]
22. Gene augmentation trials using the Rpe65-deficient dog: contributions towards development and refinement of human clinical trials.
Petersen-Jones SM; Annear MJ; Bartoe JT; Mowat FM; Barker SE; Smith AJ; Bainbridge JW; Ali RR
Adv Exp Med Biol; 2012; 723():177-82. PubMed ID: 22183331
[No Abstract] [Full Text] [Related]
23. Acute radiolabeling of retinoids in eye tissues of normal and rpe65-deficient mice.
Qtaishat NM; Redmond TM; Pepperberg DR
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1435-46. PubMed ID: 12657577
[TBL] [Abstract][Full Text] [Related]
24. Retina-clock relations dictate nocturnal to diurnal behaviors.
McNeill DS; Altimus CM; Hattar S
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12645-6. PubMed ID: 18753617
[No Abstract] [Full Text] [Related]
25. Keeping an eye on clinical trials in 2008.
Bainbridge JW; Ali RR
Gene Ther; 2008 May; 15(9):633-4. PubMed ID: 18337840
[No Abstract] [Full Text] [Related]
26. Disease mechanisms and gene therapy in a mouse model for X-linked retinoschisis.
Molday LL; Min SH; Seeliger MW; Wu WW; Dinculescu A; Timmers AM; Janssen A; Tonagel F; Hudl K; Weber BH; Hauswirth WW; Molday RS
Adv Exp Med Biol; 2006; 572():283-9. PubMed ID: 17249585
[No Abstract] [Full Text] [Related]
27. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success.
Jacobson SG; Aleman TS; Cideciyan AV; Sumaroka A; Schwartz SB; Windsor EA; Traboulsi EI; Heon E; Pittler SJ; Milam AH; Maguire AM; Palczewski K; Stone EM; Bennett J
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6177-82. PubMed ID: 15837919
[TBL] [Abstract][Full Text] [Related]
28. Does constitutive phosphorylation protect against photoreceptor degeneration in Rpe65-/- mice?
Rohrer B; Ablonczy Z; Znoiko S; Redmond M; Ma JX; Crouch R
Adv Exp Med Biol; 2003; 533():221-7. PubMed ID: 15180268
[TBL] [Abstract][Full Text] [Related]
29. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.
Cideciyan AV; Aleman TS; Boye SL; Schwartz SB; Kaushal S; Roman AJ; Pang JJ; Sumaroka A; Windsor EA; Wilson JM; Flotte TR; Fishman GA; Heon E; Stone EM; Byrne BJ; Jacobson SG; Hauswirth WW
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15112-7. PubMed ID: 18809924
[TBL] [Abstract][Full Text] [Related]
30. Remaining rod activity mediates visual behavior in adult Rpe65-/- mice.
Cachafeiro M; Bemelmans AP; Canola K; Pignat V; Crippa SV; Kostic C; Arsenijevic Y
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6835-42. PubMed ID: 20702833
[TBL] [Abstract][Full Text] [Related]
31. RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-/- mice.
Chen Y; Moiseyev G; Takahashi Y; Ma JX
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1177-84. PubMed ID: 16505056
[TBL] [Abstract][Full Text] [Related]
32. RPE65 is essential for the function of cone photoreceptors in NRL-deficient mice.
Wenzel A; von Lintig J; Oberhauser V; Tanimoto N; Grimm C; Seeliger MW
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):534-42. PubMed ID: 17251447
[TBL] [Abstract][Full Text] [Related]
33. Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium.
Jin M; Li S; Moghrabi WN; Sun H; Travis GH
Cell; 2005 Aug; 122(3):449-59. PubMed ID: 16096063
[TBL] [Abstract][Full Text] [Related]
34. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog.
Narfström K; Katz ML; Bragadottir R; Seeliger M; Boulanger A; Redmond TM; Caro L; Lai CM; Rakoczy PE
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1663-72. PubMed ID: 12657607
[TBL] [Abstract][Full Text] [Related]
35. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle.
Redmond TM; Yu S; Lee E; Bok D; Hamasaki D; Chen N; Goletz P; Ma JX; Crouch RK; Pfeifer K
Nat Genet; 1998 Dec; 20(4):344-51. PubMed ID: 9843205
[TBL] [Abstract][Full Text] [Related]
36. Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies.
den Hollander AI; Black A; Bennett J; Cremers FP
J Clin Invest; 2010 Sep; 120(9):3042-53. PubMed ID: 20811160
[TBL] [Abstract][Full Text] [Related]
37. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle.
Redmond TM; Poliakov E; Yu S; Tsai JY; Lu Z; Gentleman S
Proc Natl Acad Sci U S A; 2005 Sep; 102(38):13658-63. PubMed ID: 16150724
[TBL] [Abstract][Full Text] [Related]
38. Morphological aspects related to long-term functional improvement of the retina in the 4 years following rAAV-mediated gene transfer in the RPE65 null mutation dog.
Narfström K; Seeliger M; Lai CM; Vaegan ; Katz M; Rakoczy EP; Remé C
Adv Exp Med Biol; 2008; 613():139-46. PubMed ID: 18188938
[No Abstract] [Full Text] [Related]
39. Light aversion in mice depends on nonimage-forming irradiance detection.
Thompson S; Recober A; Vogel TW; Kuburas A; Owens JA; Sheffield VC; Russo AF; Stone EM
Behav Neurosci; 2010 Dec; 124(6):821-7. PubMed ID: 21038932
[TBL] [Abstract][Full Text] [Related]
40. Correlation of regenerable opsin with rod ERG signal in Rpe65-/- mice during development and aging.
Rohrer B; Goletz P; Znoiko S; Ablonczy Z; Ma JX; Redmond TM; Crouch RK
Invest Ophthalmol Vis Sci; 2003 Jan; 44(1):310-5. PubMed ID: 12506090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
